N/A N=8 Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT) · Epistaxis
Primary: Epistaxis Severity Score (ESS) — 5.13; 3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy
Excessive Diet Restriction
Primary: Insulin Sensitivity (HOMA-IR) — 0.05; 0.06 no unit
Early Phase 1 N=12 Pressure Assessment to Improve Outcomes After TAVR: a Registry
Hypertension · Aortic Stenosis, Calcific · Quality of Life
Primary: Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Summary Score — 59.4; 74.1 score on a scale — p=0.12
N/A N=20 Vital USA Respiratory Rate Validation In Adults
Respiratory Complication
Primary: Respiratory Rate Accuracy Validation for the Vital USA Vital Detect Monitor. — 1.39 Breaths/Min
Phase 1 N=24 A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of RO7017773 (Part 1) — 1320; 1570; 1120; 1490 ng/mL
N/A N=377 Assessment of Giant Cell Arteritis Medical Practices in France
Giant Cell Arteritis
Primary: Patient Journey : Physicians Who Referred the Patient — 171; 31; 21; 17 Participants
Phase 4 N=136 Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
HIV Prevention
Primary: Adherence to PrEP — 22; 11; 30; 54 Participants
N/A N=32 Repetitive Transcranial Magnetic Stimulation for Dementia
Dementia · Mild Cognitive Impairment
Primary: Changes From Baseline CVLT Scores After Treatment and 4 Month Later — 8.5; 9.4; 8.6; 8.3 score on a scale
Phase 4 N=198 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
Heroin Dependence · Opioid-Related Disorders
Primary: Time-to-Relapse: XRNTX vs. ETAU Following Release From Jail — 8.6; 5.9 Weeks
Phase 2 N=48 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants
N/A N=170 Comparing Two Types of Endometrial Activation Prior to Embryo Transfer
Infertility · Endometrial Disorder
Primary: Number of Participants With Live Births Per Transfers Performed — 37; 43 Participants
N/A N=43 Patient Anxiety Associated With Lymphedema Surveillance Method
Anxiety
Primary: Anxiety — 7.1; 8.8 units on a scale
N/A N=19 Crohn Disease Exclusion Diet After Single Medication De-escalation
Crohn Disease
Primary: Sustained Relapse-free Remission — 6; 5 Participants
N/A N=630 Maternal Adversity, Vulnerability and Neurodevelopment
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse) · Infant Development · Infant Behavior
Primary: Child's Cognitive Development Measured Using the Bayley Scales of Infant Development II. — 524; 508; 458; 422 Participants
Phase 1 N=38 A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10) Following Each Treatment Arm — 1380; 1280 hour times picomol…